Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 2 of the 26 sources its claims cite were checked for support.

CRF Induces Intestinal Epithelial Barrier Injury via the Release of Mast Cell Proteases and TNF-α

Open access

Abstract

BACKGROUND AND AIMS: Psychological stress is a predisposing factor in the onset and exacerbation of important gastrointestinal diseases including irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). The pathophysiology of stress-induced intestinal disturbances is known to be mediated by corticotropin releasing factor (CRF) but the precise signaling pathways remain poorly understood. Utilizing a porcine ex vivo intestinal model, the aim of this study was to investigate the mechanisms by which CRF mediates intestinal epithelial barrier disturbances. METHODOLOGY: Ileum was harvested from 6-8 week-old pigs, mounted on Ussing Chambers, and exposed to CRF in the presence or absence of various pharmacologic inhibitors of CRF-mediated signaling pathways. Mucosal-to-serosal flux of 4 kDa-FITC dextran (FD4) and transepithelial electrical resistance (TER) were recorded as indices of intestinal epithelial barrier function. RESULTS: Exposure of porcine ileum to 0.05-0.5 µM CRF increased (p<0.05) paracellular flux compared with vehicle controls. CRF treatment had no deleterious effects on ileal TER. The effects of CRF on FD4 flux were inhibited with pre-treatment of tissue with the non-selective CRF(1/2) receptor antagonist Astressin B and the mast cell stabilizer sodium cromolyn (10(-4) M). Furthermore, anti-TNF-α neutralizing antibody (p<0.01), protease inhibitors (p<0.01) and the neural blocker tetrodotoxin (TTX) inhibited CRF-mediated intestinal barrier dysfunction. CONCLUSION: These data demonstrate that CRF triggers increases in intestinal paracellular permeability via mast cell dependent release of TNF-α and proteases. Furthermore, CRF-mast cell signaling pathways and increases in intestinal permeability require critical input from the enteric nervous system. Therefore, blocking the deleterious effects of CRF may address the enteric signaling of mast cell degranulation, TNFα release, and protease secretion, hallmarks of IBS and IBD.

Overview

CoChat Summary

TL;DR

Using an ex vivo porcine ileum Ussing chamber model, the paper shows that CRF increases paracellular permeability without changing TER. The barrier effect depends on mast cell degranulation, TNF-α and protease activity, and requires enteric neural signaling.

Key findings

  • CRF at 0.05, 0.1, and 0.5 µM increased FD4 flux across porcine ileal mucosa compared with vehicle controls (p<0.05), but did not affect TER over 180 min.
  • Astressin B (1 µM) prevented CRF-induced increases in FD4 flux, indicating CRF receptor-mediated effects.
  • 0.5 µM CRF induced mast cell degranulation and increased release of mast cell tryptase and TNF-α; sodium cromolyn (10−4 M) blocked mast cell degranulation, FD4 flux increases, and TNF-α elevation.
  • Protease inhibitors and anti-TNF-α each inhibited CRF-stimulated FD4 flux (p<0.01), and TTX blocked both baseline and CRF-mediated mast cell degranulation and FD4 flux.

Methods

  • Ex vivo study using ileum from 6–8 week-old pigs mounted in Ussing chambers; tissues were exposed to CRF with or without pharmacologic inhibitors.
  • Barrier function was assessed by mucosal-to-serosal FD4 flux and transepithelial electrical resistance (TER); additional readouts included histology, mast cell degranulation counts, TNF-α ELISA, tryptase assay, and occludin immunofluorescence.
  • Statistical analysis used one-way ANOVA with Fisher’s LSD post hoc test; mast cell counts used the Mann-Whitney test.

Limitations

  • The paper states that the pharmacologic approach could not distinguish whether CRF effects were mediated by direct mast cell receptor activation or indirectly via enteric neurons, because CRF receptors are expressed on both.
  • The authors note they could not discern which specific mast cell proteases were responsible because the protease inhibitor cocktail contained inhibitors of both tryptase and chymase.
  • Evident from the text: the work is an ex vivo porcine ileum model, so the findings are not direct in vivo or human clinical evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0039935

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 CRF induces elevations in FD4 flux in porcine ileum. Porcine ileum was placed on Ussing Chambers and treated with CRF at increasing concentrations (0.05, 0.1, and 0.5 µM) and the rate of FD4 flux was measured over a 180-minute period. CRF at all concentrations induced elevations in FD4 flux (p<0.01) with the highest FD4 flux rates observed with 0.5 µM CRF. Data for each experimental treatment are expressed as means ± SE for n = 6−8 pigs. Symbols (*,†) differ from other treatments by p<0.05; ANOVA.
Figure 1 CRF induces elevations in FD4 flux in porcine ileum. Porcine ileum was placed on Ussing Chambers and treated with CRF at increasing concentrations (0.05, 0.1, and 0.5 µM) and the rate of FD4 flux was measured over a 180-minute period. CRF at all concentrations induced elevations in FD4 flux (p<0.01) with the highest FD4 flux rates observed with 0.5 µM CRF. Data for each experimental treatment are expressed as means ± SE for n = 6−8 pigs. Symbols (*,†) differ from other treatments by p<0.05; ANOVA.CC BY · PubMed Central
Figure 2 CRF-induced FD4 flux is Prevented with Astressin B. CRF (0.5 µM) induced elevations in the rate of FD4 flux across the porcine ileum mounted on Ussing chambers. Pre-treatment of ileal mucosa with Astressin B (1 µM) 30 minutes prior to CRF exposure prevented CRF-mediated increases in FD4 flux rates. Data for each experimental treatment are expressed as means ± SE for n = 6−8 pigs. Symbols (*,†) differ from other treatments by p<0.05; ANOVA.
Figure 2 CRF-induced FD4 flux is Prevented with Astressin B. CRF (0.5 µM) induced elevations in the rate of FD4 flux across the porcine ileum mounted on Ussing chambers. Pre-treatment of ileal mucosa with Astressin B (1 µM) 30 minutes prior to CRF exposure prevented CRF-mediated increases in FD4 flux rates. Data for each experimental treatment are expressed as means ± SE for n = 6−8 pigs. Symbols (*,†) differ from other treatments by p<0.05; ANOVA.CC BY · PubMed Central
Figure 3 Histological appearance of CRF-treated porcine ileal mucosa on Ussing chambers. Ileal histology (20× magnification) of hematoxylin and eosin-stained porcine ileal sections after 180 minutes on Ussing chamber following treatment with vehicle control (A) or 0.5 µM CRF (B). Images are representative of ileal sections from n = 6 pigs/treatment.
Figure 3 Histological appearance of CRF-treated porcine ileal mucosa on Ussing chambers. Ileal histology (20× magnification) of hematoxylin and eosin-stained porcine ileal sections after 180 minutes on Ussing chamber following treatment with vehicle control (A) or 0.5 µM CRF (B). Images are representative of ileal sections from n = 6 pigs/treatment.CC BY · PubMed Central
Figure 4 Occludin localization in porcine ileum exposed to CRF. In control (vehicle-treated) tissues (A), occludin (green) was localized predominantly to the interepithelial tight junctions as demonstrated by the epithelial membrane staining patterns whereas CRF-treated tissues (B) exhibited a disrupted occluding staining pattern. Images are representative of tissues from n = 3 pigs.
Figure 4 Occludin localization in porcine ileum exposed to CRF. In control (vehicle-treated) tissues (A), occludin (green) was localized predominantly to the interepithelial tight junctions as demonstrated by the epithelial membrane staining patterns whereas CRF-treated tissues (B) exhibited a disrupted occluding staining pattern. Images are representative of tissues from n = 3 pigs.CC BY · PubMed Central
Figure 5 Histologic analysis of CRF-mediated intestinal mast cell degranulation. Treatment of porcine ileal tissues mounted on Ussing chambers with CRF caused and increase in mast cell degranulation as determined by toluidine blue staining. Arrows indicate the release of mast cell granules into surrounding tissues. Sodium cromolyn, a mast cell stabilizing agent, prevented CRF-induced mast cell degranulation. Figures are representative of ileal tissue sections from n = 4 pigs.
Figure 5 Histologic analysis of CRF-mediated intestinal mast cell degranulation. Treatment of porcine ileal tissues mounted on Ussing chambers with CRF caused and increase in mast cell degranulation as determined by toluidine blue staining. Arrows indicate the release of mast cell granules into surrounding tissues. Sodium cromolyn, a mast cell stabilizing agent, prevented CRF-induced mast cell degranulation. Figures are representative of ileal tissue sections from n = 4 pigs.CC BY · PubMed Central
Figure 6 The role of mast cell activation in CRF-mediated changes in FD4 flux. Treatment of porcine ileal tissues mounted on Ussing chambers with CRF increased mast cell degranulation indicated by the increased percentage of degranulated mast cells (C) and the increased release of mast cell tryptase (A) and TNF-α (B). Treatment of porcine ileal tissues with cromolyn sodium 30 minutes prior to exposure to 0.5 µM CRF blocked mast cell degranulation (C) and TNF-α release (B) and prevented CRF-mediated increases in FD4 permeability (D). c48/80 (5 µg/mL) induced marked degranulation of mast cells (C) and increases in FD4 flux (D) that were inhibited with sodium cromolyn. Data for each FD4 flux experiments are expressed as means ± SE for n = 6−8 pigs. Symbols (*,†) differ from other treatments by p<0.05; ANOVA.
Figure 6 The role of mast cell activation in CRF-mediated changes in FD4 flux. Treatment of porcine ileal tissues mounted on Ussing chambers with CRF increased mast cell degranulation indicated by the increased percentage of degranulated mast cells (C) and the increased release of mast cell tryptase (A) and TNF-α (B). Treatment of porcine ileal tissues with cromolyn sodium 30 minutes prior to exposure to 0.5 µM CRF blocked mast cell degranulation (C) and TNF-α release (B) and prevented CRF-mediated increases in FD4 permeability (D). c48/80 (5 µg/mL) induced marked degranulation of mast cells (C) and increases in FD4 flux (D) that were inhibited with sodium cromolyn. Data for each FD4 flux experiments are expressed as means ± SE for n = 6−8 pigs. Symbols (*,†) differ from other treatments by p<0.05; ANOVA.CC BY · PubMed Central
Figure 7 Neutralization of TNF-α and protease activity inhibits CRF-induced increases in FD4 flux in porcine ileum. Pretreatment of porcine ileum mounted on Ussing chambers with neutralizing anti-TNF-α antibody prevented CRF –induced increased in FD4 flux. Pre-treatment of porcine ileum with a protease inhibitor (PI) cocktail reduced baseline FD4 flux values and CRF-induced increases in FD4 flux. Values represent means SE; n = 6−8 animals. Symbols (*,†) differ from other treatments by p<0.05.
Figure 7 Neutralization of TNF-α and protease activity inhibits CRF-induced increases in FD4 flux in porcine ileum. Pretreatment of porcine ileum mounted on Ussing chambers with neutralizing anti-TNF-α antibody prevented CRF –induced increased in FD4 flux. Pre-treatment of porcine ileum with a protease inhibitor (PI) cocktail reduced baseline FD4 flux values and CRF-induced increases in FD4 flux. Values represent means SE; n = 6−8 animals. Symbols (*,†) differ from other treatments by p<0.05.CC BY · PubMed Central
Figure 8 The Role of the enteric nervous system in CRF-mediated mast cell activation and FD4 flux. Toluidine blue staining of histological sections (100 X magnification) (A) and quantitation of the % of degranulated tissue mast cells (B) in porcine ileum revealed increased degranulation of mast cells in CRF–treated tissues. Treatment of ileal tissues with tetrodotoxin (TTX) inhibited mast cell degranulation and FD4 flux (C) under basal and CRF-stimulated conditions and inhibited. For histological analysis, values represent means ± SE; n = 6 animals and are presented as the percentage of total cell count per treatment at 20× magnification. FD4 flux values represent means ± SE; n = 6−8 animals Symbols (*,†) differs significantly by p<0.05 from vehicle control.
Figure 8 The Role of the enteric nervous system in CRF-mediated mast cell activation and FD4 flux. Toluidine blue staining of histological sections (100 X magnification) (A) and quantitation of the % of degranulated tissue mast cells (B) in porcine ileum revealed increased degranulation of mast cells in CRF–treated tissues. Treatment of ileal tissues with tetrodotoxin (TTX) inhibited mast cell degranulation and FD4 flux (C) under basal and CRF-stimulated conditions and inhibited. For histological analysis, values represent means ± SE; n = 6 animals and are presented as the percentage of total cell count per treatment at 20× magnification. FD4 flux values represent means ± SE; n = 6−8 animals Symbols (*,†) differs significantly by p<0.05 from vehicle control.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 14 Not checked · 28 Own results and interpretations

21 more claims

Create a free account to see all 42 claims and to verify the 24 references still open.

See all claims — free account
  • It may state two separate claims as one. 10
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 209

Metadata

Authors
Overman, E. L., Rivier, J. E., & Moeser, A. J.
Affiliations
  • North Carolina State University (US)
  • Salk Institute for Biological Studies (US)
Corresponding author
Moeser, Adam J.
Venue
PLoS ONE
Published
2012-06-29
Volume
7
Issue
6
Pages
e39935
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2125432409
Cited by
207
References
52
Citations by year
2026: 8 · 2025: 9 · 2024: 10 · 2023: 18 · 2022: 17 · 2021: 13 · 2020: 19 · 2019: 17 · 2018: 17 · 2017: 26 · 2016: 12 · 2015: 14 · 2014: 15 · 2013: 8 · 2012: 3
FWCI
12.42
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (DK-34987)
  • U.S. Public Health Service (DKPO1026741)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K08DK084313, P30‐DK34987, P30DK034987)
  • Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina at Chapel Hill (P30 DK34987, DK34987)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
Keywords
corticotropin-releasing factor, psychological stress, intestinal epithelial barrier, intestinal permeability, mast cell degranulation, mast cell proteases, TNF-α, enteric nervous system, tetrodotoxin, irritable bowel syndrome, inflammatory bowel disease, porcine ileum, transepithelial electrical resistance
MeSH terms
Animals, Corticotropin-Releasing Hormone, Dextrans, Ileum, Intestinal Mucosa, Mast Cells, Molecular Weight, Neutralization Tests, Peptide Fragments, Peptide Hydrolases, Permeability, Protease Inhibitors, Tumor Necrosis Factor-alpha, Cell Degranulation, Fluorescein-5-isothiocyanate, Enteric Nervous System, Protein Transport, Sus scrofa, Rats, Occludin, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRF Induces Intestinal Epithelial Barrier Injury via the Release of Mast Cell Proteases and TNF-α. https://app.cochat.ai/papers/10.1371/journal.pone.0039935
The paper
Overman, E. L., Rivier, J. E., & Moeser, A. J. (2012). CRF Induces Intestinal Epithelial Barrier Injury via the Release of Mast Cell Proteases and TNF-α. PLoS ONE. https://doi.org/10.1371/journal.pone.0039935

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.